Nelleke P M Brouwer1, Dave E W van der Kruijssen2, Niek Hugen3, Ignace H J T de Hingh4, Iris D Nagtegaal5, Rob H A Verhoeven3,6, Miriam Koopman2, Johannes H W de Wilt3. 1. Department of Surgery, Radboud University Medical Center, Nijmegen, The Netherlands. nelleke.brouwer@radboudumc.nl. 2. Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands. 3. Department of Surgery, Radboud University Medical Center, Nijmegen, The Netherlands. 4. Department of Surgery, Catharina Hospital Eindhoven, Eindhoven, The Netherlands. 5. Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands. 6. Department of Research, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, The Netherlands.
Abstract
PURPOSE: We explored differences in survival between primary tumor locations, hereby focusing on the role of metastatic sites in synchronous metastatic colorectal cancer (mCRC). METHODS: Data for patients diagnosed with synchronous mCRC between 1989 and 2014 were retrieved from the Netherlands Cancer registry. Relative survival and relative excess risks (RER) were analyzed by primary tumor location (right colon (RCC), left colon (LCC), and rectum). Metastatic sites were reported per primary tumor location. Survival was analyzed for metastatic sites combined and for single metastatic sites. RESULTS: In total, 36,297 patients were included in this study. Metastatic sites differed significantly between primary tumor locations, with liver-only metastases in 43%, 54%, and 52% of RCC, LCC, and rectal cancer patients respectively (p < 0.001). Peritoneal metastases were most prevalent in RCC patients (33%), and lung metastases were most prevalent in rectal cancer patients (28%). Regardless of the location of metastases, patients with RCC had a worse survival compared with LCC (RER 0.81, 95% CI 0.78-0.83) and rectal cancer (RER 0.73, 95% CI 0.71-0.76). The survival disadvantage for RCC remained present, even in cases with metastasectomy for liver-only disease (LCC: RER 0.66, 95% CI 0.57-0.76; rectal cancer: RER 0.84, 95% CI 0.66-1.06). CONCLUSIONS: This study showed significant differences in relative survival between primary tumor locations in synchronous mCRC, which can only be partially explained by distinct metastatic sites. Our findings support the concept that RCC, LCC and rectal cancer should be considered distinct entities in synchronous mCRC.
PURPOSE: We explored differences in survival between primary tumor locations, hereby focusing on the role of metastatic sites in synchronous metastatic colorectal cancer (mCRC). METHODS: Data for patients diagnosed with synchronous mCRC between 1989 and 2014 were retrieved from the Netherlands Cancer registry. Relative survival and relative excess risks (RER) were analyzed by primary tumor location (right colon (RCC), left colon (LCC), and rectum). Metastatic sites were reported per primary tumor location. Survival was analyzed for metastatic sites combined and for single metastatic sites. RESULTS: In total, 36,297 patients were included in this study. Metastatic sites differed significantly between primary tumor locations, with liver-only metastases in 43%, 54%, and 52% of RCC, LCC, and rectal cancerpatients respectively (p < 0.001). Peritoneal metastases were most prevalent in RCCpatients (33%), and lung metastases were most prevalent in rectal cancerpatients (28%). Regardless of the location of metastases, patients with RCC had a worse survival compared with LCC (RER 0.81, 95% CI 0.78-0.83) and rectal cancer (RER 0.73, 95% CI 0.71-0.76). The survival disadvantage for RCC remained present, even in cases with metastasectomy for liver-only disease (LCC: RER 0.66, 95% CI 0.57-0.76; rectal cancer: RER 0.84, 95% CI 0.66-1.06). CONCLUSIONS: This study showed significant differences in relative survival between primary tumor locations in synchronous mCRC, which can only be partially explained by distinct metastatic sites. Our findings support the concept that RCC, LCC and rectal cancer should be considered distinct entities in synchronous mCRC.
Authors: Felice N van Erning; Marloes A Elferink; Amanda C R K Bos; Valery E P P Lemmens Journal: J Natl Cancer Inst Date: 2015-09 Impact factor: 13.506
Authors: Nele Boeckx; Reija Koukakis; Ken Op de Beeck; Christian Rolfo; Guy Van Camp; Salvatore Siena; Josep Tabernero; Jean-Yves Douillard; Thierry André; Marc Peeters Journal: Clin Colorectal Cancer Date: 2018-03-08 Impact factor: 4.481
Authors: Lydia G M van der Geest; Jorine't Lam-Boer; Miriam Koopman; Cees Verhoef; Marloes A G Elferink; Johannes H W de Wilt Journal: Clin Exp Metastasis Date: 2015-04-22 Impact factor: 5.150
Authors: Julian Walter Holch; Ingrid Ricard; Sebastian Stintzing; Dominik Paul Modest; Volker Heinemann Journal: Eur J Cancer Date: 2016-11-29 Impact factor: 9.162
Authors: Timothy J Price; Carol Beeke; Shahid Ullah; Robert Padbury; Guy Maddern; David Roder; Amanda R Townsend; James Moore; Amitesh Roy; Yoko Tomita; Christos Karapetis Journal: Cancer Date: 2014-11-06 Impact factor: 6.860
Authors: Fotios Loupakis; Dongyun Yang; Linda Yau; Shibao Feng; Chiara Cremolini; Wu Zhang; Martin K H Maus; Carlotta Antoniotti; Christiane Langer; Stefan J Scherer; Thomas Müller; Herbert I Hurwitz; Leonard Saltz; Alfredo Falcone; Heinz-Josef Lenz Journal: J Natl Cancer Inst Date: 2015-02-24 Impact factor: 13.506
Authors: Paolo Goffredo; Alan F Utria; Anna C Beck; Yun Shin Chun; James R Howe; Ronald J Weigel; Jean-Nicolas Vauthey; Imran Hassan Journal: J Gastrointest Surg Date: 2018-10-01 Impact factor: 3.452
Authors: Nelleke P M Brouwer; Amanda C R K Bos; Valery E P P Lemmens; Pieter J Tanis; Niek Hugen; Iris D Nagtegaal; Johannes H W de Wilt; Rob H A Verhoeven Journal: Int J Cancer Date: 2018-09-29 Impact factor: 7.396
Authors: Stefan Sponholz; Selma Oguzhan; Mesut Mese; Moritz Schirren; Andreas Kirschbaum; Joachim Schirren Journal: Int J Colorectal Dis Date: 2021-03-12 Impact factor: 2.571
Authors: Natasha Leigh; Gregory A Williams; Steven M Strasberg; Ryan C Fields; William G Hawkins; Chet W Hammill; Dominic E Sanford Journal: Ann Surg Oncol Date: 2022-05-20 Impact factor: 4.339
Authors: Nadine L de Boer; Koen Rovers; Jacobus W A Burger; Eva V E Madsen; Alexandra R M Brandt-Kerkhof; Niels F M Kok; Johannes H W de Wilt; Philip H de Reuver; Amanda Bos; Ignace H J T de Hingh; Cornelis Verhoef Journal: Cancer Med Date: 2020-07-02 Impact factor: 4.452
Authors: Patricia A H Hamers; Marloes A G Elferink; Rebecca K Stellato; Cornelis J A Punt; Anne M May; Miriam Koopman; Geraldine R Vink Journal: Int J Cancer Date: 2020-07-20 Impact factor: 7.396
Authors: Seyed M Qaderi; Boris Galjart; Cornelis Verhoef; Gerrit D Slooter; Miriam Koopman; Robert H A Verhoeven; Johannes H W de Wilt; Felice N van Erning Journal: Int J Colorectal Dis Date: 2021-04-04 Impact factor: 2.571